Search

Your search keyword '"Golas, Jonathan"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Golas, Jonathan" Remove constraint Author: "Golas, Jonathan"
23 results on '"Golas, Jonathan"'

Search Results

1. Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy

2. Supplementary Methods, Figures S1-S10, and Table S1 from Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)

3. Data from Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)

4. Figure S6 from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers

5. Table S2 from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers

6. Supplementary Methods from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers

8. Cooperation Between Distinct Cancer Driver Genes Underlies Intertumor Heterogeneity in Hepatocellular Carcinoma

9. Abstract 2283: A novel GUCY2C - CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors

11. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers

12. Abstract A16: A GUCY2c-CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors

13. Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy.

14. Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors

15. Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)

17. A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.

18. Abstract 1697: Therapeutic targeting the NOTCH3 receptor with antibody drug conjugates

19. Abstract 2476: Bispecific redirected T-cell immunotherapy targeting P-cadherin expressing tumors

20. Abstract 5471: Notch-antibody drug conjugates have a different mechanism of action than Notch signaling inhibitors and induce tumor regression.

21. SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models

22. Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity

23. Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Catalog

Books, media, physical & digital resources